Sea Limited Reports Second Quarter 2025 Results
SINGAPORE–(BUSINESS WIRE)–Sea Limited (NYSE: SE) (“Sea” or the “Company”) today announced its financial results for the second quarter ended... Read more.
1Kosmos Secures $57M in Series B Funding to Accelerate Market Expansion for Identity Verification and Passwordless Authentication Platform
Led by Forgepoint Capital and Origami’s Oquirrh Ventures the investment will fuel R&D and go-to-market for capitalizing on demand for identity modernization... Read more.
Monroe Capital Supports Growth of Emerald Lake Capital Management’s Mission Critical Group
CHICAGO–(BUSINESS WIRE)–Monroe Capital LLC (“Monroe”) announced it acted as joint lead arranger on the funding of a senior credit facility to support... Read more.
Periscope Equity Announces Close of $370 Million Oversubscribed Third Fund
CHICAGO–(BUSINESS WIRE)–Periscope Equity, a Chicago-based private equity firm, today announced the closing of Periscope Equity III, L.P. (“Fund III”).... Read more.
Genesis Energy, L.P. to Participate in Citi’s 2025 Natural Resources Conference
HOUSTON–(BUSINESS WIRE)–Genesis Energy, L.P. (NYSE: GEL) announced today that it will host investor meetings at Citi’s 2025 Natural Resources Conference... Read more.
Innovative Lab Services LLC Expands Reach into the Southern California Market with the Acquisition of Prodigy Scientific, Inc
COLUMBUS, Ohio–(BUSINESS WIRE)–Innovative Lab Services LLC (“ILS”), a premier provider of laboratory solutions, is pleased to announce it has entered... Read more.
Moloco Research Uncovers Substantial Growth Opportunities for Mobile App Advertising Beyond Google and Meta
Moloco reveals a disconnect: 88% of consumer mobile app ad spend remains with Google and Meta, despite user attention shifting elsewhere New study finds advertisers... Read more.
KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
First and only systemic therapy to improve survival when used before and after surgery for patients with MIBC who are ineligible for cisplatin-based chemotherapy... Read more.
PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible... Read more.
Swiss Firms Seek Partners to Fight Cybersecurity Threats
Talent shortages, rising cyberattacks increase demand for external services as companies grow more dependent on IT system defenses, ISG Provider Lens® report says... Read more.